{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-015744","form_type":"8-K","ticker":"COGT","cik":"0001622229","company_name":"Cogent Biosciences, Inc.","filed_at":"2022-08-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:56.391779+00:00","generated_at":"2026-06-24T02:04:27.002734+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Cogent Biosciences Q2 net loss $34.9M; cash $325.6M after June public offering","bullets":["Cash and equivalents $325.6M at June 30, 2022, up from $191M at March 31, 2022; includes $172.6M from June 2022 public offering, funds operations into 2025.","Net loss $34.9M for Q2 2022 vs $16.5M in Q2 2021; R&D expenses rose to $29.5M from $12.4M on trial costs.","Positive initial bezuclastinib APEX data: all 11 AdvSM patients achieved ≥50% serum tryptase reduction; no edema, cognitive effects or intracranial bleeding.","On-track for further APEX data by end of 2022; SUMMIT and PEAK trial data expected in 1H2023.","Appointed Fang Fang, Ph.D., as VP Biometrics; she brings over 20 years industry experience."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-015744","json":"https://secwatch.observer/filing/0000950170-22-015744.json","markdown":"https://secwatch.observer/filing/0000950170-22-015744.md","text":"https://secwatch.observer/filing/0000950170-22-015744.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1622229/000095017022015744/0000950170-22-015744-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1622229/000095017022015744/cogt-20220809.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T02:04:27.002734+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}